| ALDEYRA THERAPEUT.DL-,001 |
| USA |
| Gesundheit |
| US01438T1060 / A111X8 |
| 137 (Frankfurt) / ALDX (NASDAQ) |
| FRA:137, ETR:137, 137:GR, NASDAQ:ALDX |
| - |
| https://www.aldeyra.com/ |
|
Aldeyra Therapeutics Inc. is a biotechnology company dedicated to the development of treatments for immune-mediated diseases. Its primary function is to advance pharmaceutical innovations targeting un..
>Volltext.. |
| 220.57 Mio. EUR |
| 174.32 Mio. EUR |
| - |
| -30.34 Mio. EUR |
| -29.33 Mio. EUR |
| -0.49 EUR |
| 13.46 Mio. EUR |
| 60.69 Mio. EUR |
| -28.89 Mio. EUR |
| 2.52 |
| - |
| 46.59% |
| - |
| - |
| - |
| - |
| ALDEYRA |
| 18.03.26 |
|
||||
|
||||
|
||||
|
||||
|